EUVIMEDFaigh amach EUVIMED
Crossref

Basiliximab induction versus no induction in adult heart transplantation

Katelyn N Rudzik, Ryan M Rivosecchi, Brittany A Palmer, Gavin W Hickey, Jessica H Huston, Mary E Keebler, David J Kaczorowski, Edward T Horn iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14937 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Katelyn N Rudzik and 7 co-authors. Institution: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Antibodies, Monoclonal, Heart Transplantation. Cited 5 times so far (Crossref); 21 references.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

Background

Induction immunosuppression in heart transplant recipients varies greatly by center. Basiliximab (BAS) is the most commonly used induction immunosuppressant but has not been shown to reduce rejection or improve survival. The objective of this retrospective study was to compare rejection, infection, and mortality within the first 12 months following heart transplant in patients who received BAS or no induction.

Methods

This was a retrospective cohort study of adult heart transplant recipients given BAS or no induction from January 1, 2017 to May 31, 2021. The primary endpoint was incidence of treated acute cellular rejection (ACR) at 12‐months post‐transplant. Secondary endpoints included ACR at 90 days post‐transplant, incidence of antibody‐mediated rejection (AMR) at 90 days and 1 year, incidence of infection, and all‐cause mortality at 1 year.

Results

A total of 108 patients received BAS, and 26 patients received no induction within the specified timeframe. There was a lower incidence of ACR within the first year in the BAS group compared to the no induction group (27.7 vs. 68.2%, p < .002). BAS was independently associated with a lower probability of having a rejection event during the first 12‐months post‐transplant (hazard ratio (HR) .285, 95% confidence interval [CI] .142–.571, p < .001). There was no difference in the rate of infection and in mortality after hospital discharge at 1‐year post‐transplant (6% vs. 0%, p = .20).

Conclusion

BAS appears to be associated with greater freedom from rejection without an increase in infections. BAS may be a preferred to a no induction strategy in patients undergoing heart transplantation.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalHeart TransplantationHumansAdultBasiliximabRetrospective StudiesImmunosuppressive AgentsGraft RejectionRecombinant Fusion Proteins

Author keywords

basiliximabcorticosteroidheart transplantationimmunosuppressioninduction therapyretrospective cohort study

Substances

BasiliximabAntibodies, MonoclonalImmunosuppressive AgentsRecombinant Fusion Proteins

Authors and institutions

  • Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.

ORCID profiles: Edward T Horn

Cite

APA

Rudzik, K. N., Rivosecchi, R. M., Palmer, B. A., Hickey, G. W., Huston, J. H., Keebler, M. E., Kaczorowski, D. J., & Horn, E. T. (2023). Basiliximab induction versus no induction in adult heart transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.14937

Vancouver

Rudzik KN, Rivosecchi RM, Palmer BA, Hickey GW, Huston JH, Keebler ME, et al. Basiliximab induction versus no induction in adult heart transplantation. Clinical Transplantation. 2023. doi:10.1111/ctr.14937

BibTeX
@article{Rudzik2023,
  author = {Rudzik, Katelyn N and Rivosecchi, Ryan M and Palmer, Brittany A and Hickey, Gavin W and Huston, Jessica H and Keebler, Mary E and Kaczorowski, David J and Horn, Edward T},
  title = {Basiliximab induction versus no induction in adult heart transplantation},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14937}
}
Start for free →